{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-346919","form_type":"8-K","ticker":"KLRA","cik":"0002096997","company_name":"Kailera Therapeutics, Inc.","filed_at":"2026-08-12T20:20:55+00:00","discovered_at":"2026-08-12T20:22:00.376398+00:00","generated_at":"2026-08-12T20:22:09.876469+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kailera Q2 net loss widens to $111.3M; cash $1.17B funds into mid-2028","bullets":["Net loss $111.3M in Q2 2026 vs $28.9M in Q2 2025; R&D expense $101.1M (up from $19.5M).","Cash, equivalents and marketable securities $1,171.8M, expected to fund operations into mid-2028.","Ribupatide oral IND active; global Phase 3 obesity trial initiations planned for H1 2027.","Phase 2b high-dose ribupatide injection trial fully enrolled (264 pts); data expected mid-2027.","Appointed Nur Nicholson as CTO and Kathleen Tregoning as Chief Corporate Affairs Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-346919","json":"https://secwatch.observer/filing/0001193125-26-346919.json","markdown":"https://secwatch.observer/filing/0001193125-26-346919.md","text":"https://secwatch.observer/filing/0001193125-26-346919.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/0001193125-26-346919-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:22:09.876469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}